Oveporexton

Last updated

Oveporexton
Oveporexton.svg
Clinical data
Other namesTAK-861; TAK861
Routes of
administration 		Oral [1] [2]
Drug class Orexin OX2 receptor agonist [1] [2]
Identifiers
  • N-[(2S,3R)-2-[[3-(3,5-difluorophenyl)-2-fluorophenyl]methyl]-4,4-difluoro-1-(2-hydroxy-2-methylpropanoyl)pyrrolidin-3-yl]ethanesulfonamide
CAS Number
PubChem CID
Chemical and physical data
Formula C23H25F5N2O4S
Molar mass 520.52 g·mol−1
3D model (JSmol)
  • CCS(=O)(=O)N[C@@H]1[C@@H](N(CC1(F)F)C(=O)C(C)(C)O)CC2=C(C(=CC=C2)C3=CC(=CC(=C3)F)F)F
  • InChI=1S/C23H25F5N2O4S/c1-4-35(33,34)29-20-18(30(12-23(20,27)28)21(31)22(2,3)32)10-13-6-5-7-17(19(13)26)14-8-15(24)11-16(25)9-14/h5-9,11,18,20,29,32H,4,10,12H2,1-3H3/t18-,20+/m0/s1
  • Key:KVMGAIOTUIGROS-AZUAARDMSA-N

Oveporexton (INN Tooltip International Nonproprietary Name; developmental code name TAK-861) is an orexin receptor agonist which is under development for the treatment of narcolepsy and idiopathic hypersomnia. [1] [2] [3] It is taken by mouth. [1] [2] The drug is a selective orexin OX2 receptor agonist. [1] [2] It has wakefulness-promoting effects in monkeys and rodents. [2] Oveporexton is being developed by Takeda. [1] As of December 2024, it is in phase 3 clinical trials. [1]

See also

References

  1. 1 2 3 4 5 6 7 "Oveporexton". AdisInsight. 16 December 2024. Retrieved 26 February 2025.
  2. 1 2 3 4 5 6 Mitsukawa K, Terada M, Yamada R, Monjo T, Hiyoshi T, Nakakariya M, et al. (September 2024). "TAK-861, a potent, orally available orexin receptor 2-selective agonist, produces wakefulness in monkeys and improves narcolepsy-like phenotypes in mouse models". Scientific Reports. 14 (1): 20838. doi:10.1038/s41598-024-70594-1. PMC   11379823 . PMID   39242684.
  3. ↑ Kallweit MS, Kallweit NP, Kallweit U (29 November 2023). "Pharmacological Treatments of Sleep–Wake Disorders: Update 2023". Clinical and Translational Neuroscience. 7 (4): 42. doi: 10.3390/ctn7040042 . ISSN   2514-183X.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.